期刊文献+

丙氨酸转氨酶正常的慢性乙型肝炎病毒感染人群抗病毒治疗策略 被引量:16

Anti-virus treatment strategies for chronic hepatitis B virus infection with normal alanine aminotransferase
原文传递
导出
摘要 在中国慢性乙型肝炎病毒(HBV)感染的主要途径是母婴垂直传播或幼年期感染,因此疾病的自然史中存在免疫耐受的特殊状态。在临床上常常表现为HBV DNA高水平、乙型肝炎病毒e抗原(HBeAg)阳性和丙氨酸转氨酶(ALT)正常,肝组织没有或仅有轻微的炎症。对于这些ALT正常的慢性HBV感染人群抗病毒治疗的问题一直是临床研究的热点。文章从ALT与HBV感染的关系、哪些ALT正常的慢性HBV感染者应该抗病毒治疗及抗病毒治疗的可行性加以阐述。 In China,chronic HBV transmits mainly by vertical transmission or infects during childhood. Clinically some patients may remain HBeAg positive with high levels of serum HBV DNA, little or no symptoms, normal alanine aminotransferase (ALT) levels,and mi|d or no inflammations of liver tissue, and this phenomenon is known as the immune tolerance phase. Anti-virus treatment of these patients has always been a hotspot in clinical research. In this paper, we discussed the correlation between ALT and HBV infection,indications of anti-virus treatments in those with normal ALT and advantages of anti-virus treatments.
作者 窦晓光
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2013年第6期454-456,共3页 Chinese Journal of Practical Internal Medicine
基金 国家科技重大专项课题(2012ZX10002003)
关键词 丙氨酸转氨酶 乙型肝炎病毒 抗病毒治疗 alanine aminotransferase hepatitis B virus anti-virus treatment
  • 相关文献

参考文献8

  • 1窦晓光.乙型肝炎病毒感染的免疫耐受状态是否需要打破[J].中华肝脏病杂志,2012,20(10):730-732. 被引量:5
  • 2Andreani T. HBV-cmviers:When is monitoring and surveillance suf- ficient? (point of view) [J]. Clinics and Research in Hepatology and Gastroenterology,2011 : 35 ( 12 ) : 813 - 818.
  • 3Croagh CM, Bell SJ,Slavin J,et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B [ J ]. Liver lnt,2010,30 (8) :1085 -1086.
  • 4Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood:special emphasis on prognostic and therapeutic implica- tion of delayed HBeAg seroconversion (Review) [J].J Viral Hep- at,2007,14(3) :147 - 152.
  • 5Faraga MM,Tedjokusumoc R,Flechtenmacher C, et al. Immune tol- erance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp 12 [ J ]. Vac- cine,2012,30(42) :6034 -6039.
  • 6Han Q ,Zhang C ,Zhang J at al. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner [ J ]. Hepatology, 20ll ,54(4) :1179 -1189.
  • 7Carey I, D'Antiga L, Bansal S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy [ J ]. J Virology, 2011,85 ( 5 ) : 2416 - 2428.
  • 8Lan P,Zhang C, Han Q,et al. Therapeutic recovery of HBV-induced hepatocyte-intrinsic immune defect reverses systemic adaptive im- mune tolerance[ J]. Hepatology. 2013 [ Epub ahead of print ].

二级参考文献14

  • 1Das A, Maini MK. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis, 2010, 28: 126-132.
  • 2Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol, 2011, 54: 1286-1296.
  • 3Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol, 2010, 52: 616-619.
  • 4Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology, 2009, 50: 661-662.
  • 5Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int, 2009, 29: 100-107.
  • 6Andreani T. HBV-carriers: when is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol, 2011, 35: 813-818.
  • 7Kumar M, Satin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology, 2008, 134: 1376-1384.
  • 8Croagh CM, Bell S J, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int, 2010, 30: 1115-1122.
  • 9Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase. Hepatology, 2007, 46: 395-401.
  • 10Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295: 65-73.

共引文献4

同被引文献175

引证文献16

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部